

Novel biomarkers for prostate cancer prediction

Poster Session 31

Sunday, 13 March
12:15 - 13:45

Location: Room Madrid (Hall B2, level 0)

Chairs: P-A. Abrahamsson, Malmö (SE)
P. Cornford, Liverpool (GB)
N. Suardi, Milan (IT)

Aims and objectives of this presentation

The session focuses on performance characteristics of novel biomarkers and multivariable models to predict prostate cancer and its grading

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*380

Novel long non-protein coding RNAs as biomarkers and potential therapeutic targets for prostate cancer

By: Christ-Breulmann S.¹, Horn E.², Puppel S-H.¹, Buschmann T.¹, Reiche K.¹, Specht M.¹, Bertram C.¹, Friedrich M.¹, Blumert C.¹, Binder S.¹, Hackermüller J.³, Kreuz M.⁴, Löffler M.⁴, Toma M.I.⁵, Muders M.⁵, Baretton G.B.⁵, Fröhner M.⁶, Füssel S.⁶, Wirth M.⁶

Institutes:¹Fraunhofer Institute for Cell Therapy and Immunology, Dept. of Diagnostics, Leipzig, Germany, ²University of Leipzig, Institute of Clinical Immunology, Leipzig, Germany, ³Helmholtz Centre for Environmental Research, Young Investigator Group Bioinformatics & Transcriptomics, Leipzig, Germany, ⁴University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, Germany, ⁵University Hospital "Carl Gustav Carus", Technical University Dresden, Institute of Pathology, Dresden, Germany, ⁶University Hospital "Carl Gustav Carus", Technical University Dresden, Dept. of Urology, Dresden, Germany

*381

The 4Kscore predicts the grade and stage of prostate cancer in the radical prostatectomy specimen: Results from a multi-institutional prospective trial

By: Punnen S.¹, Nahar B.¹, Pavan N.¹, Sjoberg D.², Zappala S.³, Parekh D.¹

Institutes:¹University of Miami Miller School of Medicine, Dept. of Urology, Miami, United States of America, ²Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ³Andover Urology, Dept. of Urology, Andover, United States of America

*382

The 4kscore® test is comparable to biopsy in accurately predicting high-grade cancer in radical prostatectomy specimens with potential implications for active surveillance

By: Alcaraz A.¹, Newmark J.², Casariego J.³, Dong Y.², Sant G.², Mathur M.², Steiner M.²

Institutes:¹Hospital Clinic, Dept. of Urology, Barcelona, Spain, ²OPKO Health, Inc., Dept. of Medical Affairs and Diagnostics, Miami, United States of America, ³OPKO Health Europe, Dept. of Medical, Barcelona, Spain

*383

Multicenter validation study of a urine-based molecular biomarker algorithm to predict high-grade prostate cancer

By: Hendriks R.J.¹, Dijkstra S.¹, Trooskens G.⁹, Van Criekinge W.⁹, Cornel E.B.², Jannink S.A.³, De Jong H.³, Hessels D.³, Smit F.P.³, Melchers W.J.G.¹, Leyten G.H.J.M.¹, De Reijke T.M.⁴, Vergunst H.⁵, Kil P.⁶, Knipscheer B.C.⁷, Hulsbergen-Van De Kaa C.A.⁸, Mulders P.F.A.¹, Van Oort I.M.¹, Van Neste L.¹⁰, Schalken J.A.¹

Institutes:¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²ZGT Hospital, Dept. of Urology, Hengelo, The Netherlands, ³Noviogendix, Dept. of Research and Development, Nijmegen, The Netherlands, ⁴AMC University Medical Centre, Dept. of Urology, Amsterdam, The Netherlands, ⁵CWZ Hospital, Dept. of Urology, Nijmegen, The Netherlands, ⁶St Elisabeth Hospital, Dept. of

Urology, Tilburg, The Netherlands, ⁷Scheper Hospital, Dept. of Urology, Emmen, The Netherlands, ⁸Radboudumc, Dept. of Pathology, Nijmegen, The Netherlands, ⁹Ghent University, Laboratory of Bioinformatics and Computational Genomics, Ghent, Belgium, ¹⁰Maastricht University Medical Center, GROW - School for Oncology and Developmental Biology, Dept. of Pathology, Maastricht, The Netherlands

- *384 **The Prostate Health Index (PHI) predicts positive cancer biopsies in men with a negative mpMRI in a repeat biopsy population**
By: Gnanapragasam V.J.¹, Burling K.⁶, George A.¹, Kastner C.², Doble A.², Barret T.³, Koo B.⁴, Gallagher F.³, Warren A.⁵, Ragab M.²
Institutes:¹University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, ²Cambridge University Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom, ³University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom, ⁴Cambridge University Hospitals NHS Foundation Trust, Dept. of Radiology, Cambridge, United Kingdom, ⁵Cambridge University Hospitals NHS Foundation Trust, Dept. of Pathology, Cambridge, United Kingdom, ⁶Cambridge University Hospitals NHS Foundation Trust, Core Biochemical Assay Laboratory, Cambridge, United Kingdom
- *385 **The ERSPC risk calculator significantly outperforms the PCPT 2.0 in the prediction of prostate cancer: A multi-institutional study**
By: Foley B.W.¹, Gorman L.², Murphy K.³, Lunden D.², Durkan G.⁴, Power R.⁵, O'Brien F.⁶, O'Malley K.J.⁷, Galvin D.J.⁸, Murphy B.³, Watson R.W.²
Institutes:¹University College Dublin, UCD School of Medicine, Dublin, Ireland, ²University College Dublin, UCD Conway Institute of Biomolecular and Biomedical Research, Dublin, Ireland, ³University College Dublin, UCD School of Mathematics, Dublin, Ireland, ⁴University College Galway, Department of Urology, Galway, Ireland, ⁵Beaumont Hospital, Department of Urology, Dublin, Ireland, ⁶University Hospital Waterford, Department of Urology, Waterford, Ireland, ⁷Mater Misericordiae University Hospital, Department of Urology, Dublin, Ireland, ⁸St. Vincent's University Hospital, Department of Urology, Dublin, Ireland
- *386 **PCA3 and T2-ERG add further predictive and clinical benefit to the detection of prostate cancer in men of various ages in the early detection research network (EDRN)**
By: O'Malley P.¹, Golombos D.¹, Lewicki P.¹, Al Hussein Al Awamlh B.¹, Christos P.², Sanda M.³, Thompson IM⁴, Wei J.⁵, Rubin M.⁶, Barbieri C.¹, Scherr D.¹
Institutes:¹Weill Cornell Medical College, Dept. of Urology, New York, United States of America, ²Weill Cornell Medical College, Dept. of Healthcare Policy and Research, New York, United States of America, ³Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, ⁴University of Texas Health Science Center At San Antonio, Dept. of Urology, San Antonio, United States of America, ⁵University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ⁶Weill Cornell Medical College, Dept. of Pathology and Laboratory Medicine, New York, United States of America
- *387 **Identification of population-specific genetic risk profiles in young individuals with or without family history of prostate cancer**
By: Cucchiara V.¹, Zoccolillo M.², Vizziello D.³, Lazarevic D.², Cittaro D.², Ferrara A.M.¹, Gandaglia G.¹, Fossati N.¹, Benigni F.¹, Bianchi M.E.⁴, Montorsi F.¹, Briganti A.¹
Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Center For Translational Genomics and Bioinformatics, Milan, Italy, ³IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ⁴IRCCS Ospedale San Raffaele, Dept. of Genetics and Cell Biology, Milan, Italy
- *388 **Genetic variations in the OPG and RANKL genes are associated with prostate cancer risk**
By: Ney J.², Saar M.¹, Juhasz-Boess I.², Assmann G.³, Kasoha M.², Solomayer E-F.², Stöckle M.¹, Jung V.¹
Institutes:¹UKS Universitätsklinikum des Saarlandes, Dept. of Urology & Paediatric, Homburg/Saar, Germany, ²UKS Universitätsklinikum des Saarlandes, Dept. of Gynaecology, Obstetrics and Reproductive Medicine, Homburg/Saar, Germany, ³UKS Universitätsklinikum des Saarlandes, Internal Medicine I, Jose-Carreras-Center For Immuno- and Gene Therapy, Homburg/Saar, Germany

- *389 **Performance of a validated urine-exosome gene signature on initial biopsy in the 4-10ng/mL PSA gray zone: Assessment of avoided biopsies and impact of an adjusted cut-point**
By: [Donovan M.](#)¹, Bentink S.², Noerholm M.³, O'Neill V.⁴, Skog J.⁵
Institutes:¹Icahn School Of Medicine At Mt. Sinai, Dept. of Pathology, New York City, United States of America, ²Exosome Diagnostics GmbH, Dept. of Biostatistics, Martinsreid, Germany, ³Exosome Diagnostics GmbH, Dept. of Product Development, Martinsreid, Germany, ⁴Exosome Diagnostics, Clinical, Cambridge, United States of America, ⁵Exosome Diagnostics, Dept. of R&D, Cambridge, United States of America
- *390 **Micromechanical biomarkers are superior to conventional DRE and TRUS biopsy in the detection of prostate cancer**
By: [Good D.](#)¹, Hammer S.², Scanlan P.², Stewart G.¹, Phipps S.³, Shu W.², Reuben R.², McNeill A.³
Institutes:¹University of Edinburgh, Edinburgh Urological Cancer Group, Edinburgh, United Kingdom, ²Heriot Watt University, Dept. of Engineering, Edinburgh, United Kingdom, ³NHS Lothian, Dept. of Urology, Edinburgh, United Kingdom
- *391 **How accurate is the PSA test? A prevalence study of disturbed PSA values in a tertiary referral hospital**
By: [Poyet C.](#)¹, Saba K.¹, Lautenbach N.¹, Saleh L.², Umbehr M.³, Sulser T.¹, Müntener M.³, Von Eckardstein A.²
Institutes:¹Universitätsspital Zürich, Dept. of Urology, Zürich, Switzerland, ²Universitätsspital Zürich, Institut Für Klinische Chemie, Zürich, Switzerland, ³Stadtsptal Triemli Zürich, Dept. of Urology, Zürich, Switzerland
- 13:28 - 13:35 **Summary and context**
N. Suardi, Milan (IT)